FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 668 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2... August 29, 2025 Preventing Chemo Brain? Study Identifies Potential Approach for Common Problem November 2, 2022 Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma December 10, 2025 COVID-19 Testing: What you need to know. August 19, 2020 Load more HOT NEWS Strengthening EU Support for Rare Cancers under the 2028–2034 Multiannual Financial... Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer 7 ways we’ve influenced progress in lung cancer I Received the COVID-19 Vaccine – Now What?
